Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLB vs ITM for Post-Cesarean Pain
NCT04368364Phase 4Terminated
- Sponsor
- UTHealth Houston
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 4 trial of bupivacaine hydrochloride 0.75% injection, ropivacaine hydrochloride liposomal suspension injection in postoperative pain, sponsored by UTHealth Houston. Started May 2020; status: terminated.
02
Drugs
bupivacaine hydrochloride 0.75% injectionropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04368364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368364.